Rohit Malde

Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide PSA response does not guarantee disease control. Imaging surveillance remains mandatory,

⚠️ Proton Pump Inhibitor (PPI) Contraindications & Important Interactions with Anticancer Drugs PPIs (pantoprazole, omeprazole, rabeprazole, esomeprazole) are extremely common in oncology patients, yet many oral targeted therapies require acidic gastric pH for optimal absorption. This practical infographic highlights: • High-risk interactions (Dasatinib, Erlotinib, Pazopanib, Acalabrutinib & more) • BTK inhibitors, Capecitabine, CDK4/6 inhibitors • Clinical impact & real-world consequences • Safer alternatives & management strategies • Key clinical pearls for daily practice Critical for every medical oncologist! Save | Share | Tag a colleague who needs this 👇 Made with ❤️ by Dr Rupam Manna Cancer Concepts Explained Follow for more → @DrRupamOncology #Oncology #DrugInteractions #TKI #PPI #MedEd #MedTwitter #CancerCare #CancerConceptsExplained

Brain Mets burden : India Infrastructure Gap

🚨 Landmark SOFT & TEXT Trials – Practice-Changing Insights for Premenopausal HR+ Early Breast Cancer Ovarian function suppression (OFS) + Exemestane is one of the most effective endocrine strategies in higher-risk patients. Risk-adapted therapy is key: ✅ Low-risk → Tamoxifen alone ✅ Young, node+, chemo-treated, high-grade → OFS + AI Maximal estrogen deprivation works. 15-year data confirms durable DFS & distant recurrence benefit. Full visual summary of trial designs, results, toxicities & guidelines in the infographic 👇 #BreastCancer #Oncology #SOFTTrial #TEXTTrial #EndocrineTherapy #HRPositive #PremenopausalBC #CancerResearch Follow for more evidence-based visuals → @DrRupamOncology

Mayo Clinic Study: De Escalation by Omitting SLNB does not increase use of RT in careful select group patients

Peak into Long term and unknown Cumulative Late GU Toxicity from Ultrahypofractionation in Prostate Cancer @5-10 years PACE B HYPORT PC

@jesusfuel Older Machines (Early M6/G4): 60 mins or longer, often due to slower imaging, more beam paths, or using iris/cone collimators, resulting in total session times over 90 mins Newer Machines (S7, M6 with MLC) more efficient, faster Rx delivery, often may take 25-30 mins at least

@roxboxfix Who is taking 120 min on a Cyberknife tx for a 3cm cavity? Is it summing all the fractions given? Is it an older model with no Iris or MLC?

Cavity SRS Gamma Knife Vs Cyberknife Vs Linac SRS Physician Bias = Unrefutable Brief comparison from Patient Perspective What matters to Patient Their comfort Toxicity Clinical benefit Cognition Safety Cost

Update Major Perioperative IO in Resectable Gastric Cancer Real world Unfit ECOG PS2 remain challenging Chemo free Regimen looks very attractive here in Superselect pts PDL1 MSI Seem to have Massive influence in deciding its use Efficacy Updates Collected with Toxicity

🧠 LEPTOMENINGEAL METASTASIS (LM) / LEPTOMENINGEAL CARCINOMATOSIS – High-Yield Overview LM is one of the most devastating complications of advanced cancer. Tumor cells spread to the leptomeninges + CSF, causing multifocal neurologic deficits involving the brain, cranial nerves, and spine simultaneously — a classic clinical clue! This infographic covers: ✅ What is LM & the leptomeninges ✅ Pathophysiology & why incidence is rising ✅ Most common cancers (Breast, Lung — esp. EGFR/ALK/SCLC, Melanoma) ✅ Clinical features (cerebral, cranial nerve, spinal) ✅ Diagnosis (MRI “sugar-coating”, CSF analysis, advanced testing) ✅ Prognosis ✅ Goals of treatment & major modalities (Systemic therapy, Intrathecal, Radiation, Supportive care, Ommaya reservoir) ✅ Emerging concepts & practical pearls Essential reading for every oncology trainee, fellow & practicing oncologist! #LeptomeningealMetastasis #LM #NeuroOncology #CancerConceptsExplained #OncologyEducation #MedicalOncology Follow for more high-yield visuals → @DrRupamOncology

📊 EMILIA Trial Summary – The landmark Phase III study that changed second-line treatment for HER2+ metastatic breast cancer forever! T-DM1 (Trastuzumab Emtansine / Kadcyla) vs Lapatinib + Capecitabine: ✅ PFS: 9.6 vs 6.4 months
✅ OS: 30.9 vs 25.1 months
✅ Better tolerability & quality of life This practice-changing trial established T-DM1 as the new global standard, proved the power of ADCs, and opened the modern era of “smart chemotherapy.” Full visual breakdown in the infographic 👇 #HER2 #BreastCancer #Oncology #T-DM1 #ADC #EMILIATrial #PrecisionMedicine Follow for more landmark trial summaries @DrRupamOncology

Accuracy in detecting Early Stage ESCC via Different Modalities

What does one do When Surgeon operates on Presumed Early Stage (cT1) Esophageal SCC (cNo) Cancer which culminates into pT3No LVI + Surveillance PORT PO CTRT Or Immuno ( No trial yet) Found this small Ph III Chinese Trial

@DrRupamOncology Attraction 3 Trial Nivo + Chemo 3 m OS benefit

🚨 High-Yield Visual Algorithm: Management of PD-L1 Positive Metastatic Squamous NSCLC (Stage IV Squamous Cell Lung Cancer — First-Line Systemic Therapy) Practical, evidence-based decision tree covering: ✅ PD-L1 TPS stratification ✅ Pembrolizumab monotherapy (TPS ≥50%) ✅ KEYNOTE-407 chemo-immunotherapy — global standard ✅ Dual IO options & how to choose based on burden, symptoms, PS & frailty ✅ Landmark trials & current 2026 global standards Fully aligned with NCCN / ASCO / ESMO 2026 guidelines. Perfect quick reference for clinic or teaching rounds! Save this post ⬇️ | Share with your oncology team! @DrRupamOncology #NSCLC #LungCancer #SquamousNSCLC #PDL1 #Immunotherapy #KEYNOTE407 #Oncology #MedEd #OncoTwitter #CancerConceptsExplained

Incidence of PTSD after Major Oncology Surgery Site wise Prevalance + RISK Factors

Phase 2 trial of evorpacept (Anti CD47) + zanidatamab @ ESMO Breast Cancer 2026 showing exceptional efficacy in previously heavily retreated Her 2 +ve Mets Breast Cancer

Oxybutynin Vs Placebo for Hot flushes in men receiving ADT Alliance A222001 trial doi.org/10.1200/JCO-25…

ESTRO technical guideline: intensity modulated radiotherapy and image guided radiotherapy for rectal cancer doi:10.1016/j.radonc.2026.111409

Locally Advanced Squamous Cell Carcinoma of Gall Bladder T4aN1Mo

Neuroendocrine Tumors (NETs) — one-page mastery 🧬 From Ki-67 grading → classification → targeted therapy, this is the framework you need for both exams & clinics. 🔑 Remember: • Grade drives treatment • SSA = first-line (low-grade) • PRRT = game changer • NEC → treat like SCLC #MedicalOncology #NETs #Oncology #DrNB #DMOncology #OncoTwitter #MedEd #CancerEducation #PRRT #ExamPrep